Novartis’s $90 million Swiss factory to help solve cell therapy bottleneck
Novartis's $90 million Swiss factory to help solve cell therapy bottleneck 3ZURICH (Reuters) – Swiss drugmaker Novartis’s new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020. The new gene and cell therapy factory, expected to employ 450 people, will allow the …
News story posted on 2019-11-28T10:46:00.0000000Z